A study of MK-2870 for several gastrointestinal cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal, pancreatic, or bile duct cancer that cannot be removed by surgery.
- If you've had cancer treatment before, you must have recovered from any side effects from that treatment.
- You must not have had any cancer therapy (including other experimental drugs) within the last 4 weeks before starting the study.
- You must not have a history of severe eye disease.
- You must not have had or currently have a lung condition called interstitial lung disease or pneumonitis (lung inflammation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial is testing a new drug, MK-2010, alone or with other treatments for people with advanced solid tumors. The goal is to learn if it is safe and effective. Participants should be in fairly good health despite their cancer.
This trial tests an investigational drug called MK-2750 for people with certain advanced cancers that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
This trial tests a new drug called sacituzumab tirumotecan (also known as MK-2870) for people with advanced small bowel cancer that has stopped responding to standard platinum-based chemotherapy. The drug is designed to target a protein called TROP2 on cancer cells and deliver a chemo-like payload directly to them, which may help shrink or control the tumor.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.